NeuroVASx, Inc. is led by Steve Ferry who acquired and refounded NeuroVASx in 2014, and his management team, board of directors, and medical advisory board. Since 2014, NeuroVASx has made great strides in creating the necessary technology and formulating the studies to improve aneurysm outcomes.

A cerebral aneurysm - or brain aneurysm - occurs when an artery wall is weakened and blood begins to pool in a balloon-shaped cavity (aneurysm) which forms off of the parent artery wall.

Subarachnoid hemorrhage (SAH) is a serious presentation of ruptured intracranial aneurysms (IAs) that is associated with significant morbidity and mortality. Autopsy reports have shown that aneurysms are present in roughly 2-5% of the population, and it is estimated that 10-15 million persons have intracranial aneurysms in the United States, many asymptomatic.

New reimbursement codes are not expected to be needed with cPAX embolization devices, as existing intracranial aneurysm (IA) coiling procedure codes will be applicable to cPAX. cPAX can: Reduce inventory requirements in that only two (2) SKUs are anticipated for the cPAX embolization devices that will cover treatment of aneurysms - one SKU for aneurysms that are 3-7mm in size, and another SKU for aneurysms 8mm and larger.